Are Roweepra and Zarontin the Same Thing?
Roweepra (levetiracetam) and Zarontin (ethosuximide) are antiseizure (antiepileptic) drugs are used to treat different types of seizures.
Roweepra indicated for adjunctive therapy in the treatment of partial onset seizures in patients one month of age and older with epilepsy, myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.
Zarontin is used alone or in combination with other medications to treat absence seizures (also called "petit mal" seizures) in adults and children.
Side effects of Roweepra and Zarontin that are similar include drowsiness, dizziness, fatigue/tiredness, and decreased appetite.
Side effects of Roweepra that are different from Zarontin include weakness, infection, aggression, stuffy nose, and irritability.
Side effects of Zarontin that are different from Roweepra include headache, stomach upset, stomach cramps, nausea, vomiting, weight loss, diarrhea, swelling in your tongue or gums, unusual vaginal bleeding, and loss of balance or coordination.
Roweepra may also interact with other drugs.
Zarontin may also interact with other seizure medications, especially phenobarbital or phenytoin.
Antiepileptic drugs, including Roweepra, should be withdrawn gradually to minimize the potential of increased seizure frequency.
What Are Possible Side Effects of Roweepra?
Common side effects of Roweepra include:
- infection, and
Common side effects of Roweepra in children include:
- stuffy nose,
- decreased appetite, and
Antiepileptic drugs (AEDs), including Roweepra, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Tell your doctor if this occurs.
What Are Possible Side Effects of Zarontin?
Common side effects of Zarontin include:
- stomach upset,
- stomach cramps,
- loss of appetite,
- weight loss,
- swelling in your tongue or gums,
- unusual vaginal bleeding, or
- loss of balance or coordination.
A small number of people who take anticonvulsants such as Zarontin may experience depression, suicidal thoughts/attempts, or other mental/mood problems. Tell your doctor immediately if you have unusual or sudden changes in your mood, thoughts, or behavior including signs of depression, suicidal thoughts or attempts, or thoughts about harming yourself.
What Is Roweepra?
Roweepra (levetiracetam) is an antiseizure (antiepileptic) drug indicated for adjunctive therapy in the treatment of partial onset seizures in patients one month of age and older with epilepsy, myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy. Roweepra is available in generic form.
What Is Zarontin?
Zarontin (ethosuximide) is an anti-epileptic medication, also called an anticonvulsant, used alone or in combination with other medications to treat absence seizures (also called "petit mal" seizures) in adults and children. Zarontin is available in generic form.
What Drugs Interact With Roweepra?
Roweepra may interact with other drugs. Tell your doctor all medications and supplements you use.
What Drugs Interact With Zarontin?
Zarontin may interact with other seizure medications, especially phenobarbital or phenytoin. Other drugs may interact with Zarontin. Tell your doctor all prescription and over-the-counter medications and supplements you use. During pregnancy, Zarontin should be used only when prescribed. This medication passes into breast milk, but is unlikely to harm a nursing infant. Consult your doctor before breastfeeding.
How Should Roweepra Be Taken?
The Roweepra dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.
How Should Zarontin Be Taken?
The initial dose of Zarontin for patients 3 to 6 years of age is one capsule (250 mg) per day; for patients 6 years of age and older, 2 capsules (500 mg) per day. The dose thereafter is individualized according to patient response.
Brain & Nervous Resources
Health Solutions From Our Sponsors
All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).
Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.
Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.
The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.
As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.
Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.
If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.
You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.
FDA. Zarontin Product Information.